Your browser doesn't support javascript.

BVS IEC

Instituto Evandro Chagas

Home > Pesquisa > ()
XML
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

Atosiban efficacy and safety in pregnant women with threatened preterm delivery: systematic review of the literature with network meta-analysis / Eficacia y seguridad de atosiban en mujeres gestantes con diagnóstico de amenaza de parto pretérmino: revisión sistemática de la literatura con metaanálisis en red

Salazar-Castelblanco, Lina; Restrepo-Jiménez, Paula; Lasalvia, Pieralessandro; Hernández-Tarapués, Fabián; Castañeda-Cardona, Camilo; Rosselli, Diego.
Rev. colomb. obstet. ginecol ; 69(4): 270-302, Oct.-Dec. 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-985512
ABSTRACT

Objective:

To assess the efficacy and safety of atosiban in pregnant women with risk of preterm delivery as compared to nifedipine, indomethacin, terbutaline, fenoterol and placebo. Materials and

methods:

A systematic literature review was carried out in eight electronic databases, including Medline, Central, and Embase, using free and standardized search terms. Outcomes assessment included time delay until delivery, neonatal mortality, ratio of adverse maternal events, and ratio of neonatal complications. The quality of the evidence was evaluated per study and for the body of evidence and, whenever feasible, the information was synthesized into a meta-analysis. Alternatively, a narrative summary was presented.

Results:

Eleven studies were included. Atosiban did not show any statistically significant differences in terms of delaying delivery versus other uterine contraction inhibitors. The neonatal mortality was lower compared to indomethacin (RR = 0.21; 95% CI 0.05 to 0.92), and the percentage of total maternal adverse events was lower compared to fenoterol (RR = 0.16; 95% CI 0.08 to 0.31), nifedipine (RR = 0.48; 95% CI 0.3 to 0.78), and terbutaline (RR = 0.44; 95% CI 0.28 to 0.71).

Conclusions:

Atosiban has similar efficacy for delivery delay in patients with risk of preterm delivery as compared to other agents (moderate certainty), showing some advantages regarding neonatal mortality (low certainty) versus indomethacin, and compared to fenoterol, nifedipine and terbutaline in terms of maternal adverse events (moderate certainty).
Biblioteca responsável: CO76